Equities

Indaptus Therapeutics Inc

INDP:NAQ

Indaptus Therapeutics Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.05
  • Today's Change-0.015 / -1.42%
  • Shares traded9.06k
  • 1 Year change-50.00%
  • Beta1.6465
Data delayed at least 15 minutes, as of Nov 21 2024 20:58 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The Company's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.

  • Revenue in USD (TTM)0.00
  • Net income in USD-14.89m
  • Incorporated2021
  • Employees7.00
  • Location
    Indaptus Therapeutics Inc3 Columbus Circle, 15Th FloorNEW YORK 10019United StatesUSA
  • Phone+1 (646) 427-2727
  • Websitehttps://indaptusrx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kiora Pharmaceuticals Inc16.02m5.55m9.93m12.005.410.33081.780.62-0.5993-0.59934.8910.010.5889--9.181,335,000.0020.40-70.5222.75-81.86----34.64-2,040.61----0.00------3.97------
BioRestorative Therapies Inc377.00k-6.17m10.00m11.00--1.00--26.52-0.7135-0.71350.05461.440.0266--3.6934,272.73-43.49-192.11-53.99-329.3279.04---1,636.79-19,116.15----0.00--21.705.6143.67--67.77--
Imunon Inc0.00-19.45m10.05m33.00--1.23-----1.89-1.890.000.56490.00----0.00-99.63-50.18-137.53-60.27-------5,725.88----0.00---100.00--45.64--26.69--
Vaccinex Inc388.00k-18.58m10.06m37.00------25.93-12.15-12.150.2512-0.50810.1047--0.404610,486.49-501.27-262.29---------4,787.89-4,257.17---49.48----107.27-4.67-2.20---22.20--
Dominari Holdings Inc12.59m-22.69m10.23m26.00--0.2673--0.8126-3.85-3.852.116.100.2361--3.80484,192.30-42.55-26.82-44.27-27.45-----180.22-3,353.52---4.830.00----135.7512.72--63.99--
Oncotelic Therapeutics Inc0.00-4.66m10.31m22.00--1.17-----0.0115-0.01150.000.02170.00----0.00-17.29-25.03-39.98-48.76-------1,692.93---0.50090.614-------255.12------
ELEVAI Labs Inc2.45m-5.47m10.46m18.00--0.1166--4.27-0.2924-0.29240.13030.17330.38260.9499216.67135,897.80-85.53---121.34--71.15---223.57--3.40--0.00--123.50---138.94------
CeCors Inc-100.00bn-100.00bn10.46m6.00---------------0.0163------------------------------------22.70------
Indaptus Therapeutics Inc0.00-14.89m10.66m7.00--1.77-----1.72-1.720.000.58870.00----0.00-114.42-66.55-138.96-81.23------------0.00-------7.68------
Viaderma Inc17.80m2.31m10.73m75.000.00050.000031.980.60316.8416.84129.62255.590.412624.691.21237,331.305.36--6.53--28.90--12.99--2.075.660.1718---29.15---40.70------
Turnstone Biologics Corp0.00-74.42m10.86m81.00--0.2488-----3.23-3.230.001.890.00----0.00-78.42---91.27--------------0.00---73.66---78.05------
Nascent Biotech Inc0.00-1.92m10.93m-----------0.012-0.0120.00-0.0030.00-------1,256.81-708.50-----------589.83------------25.47------
Conduit Pharmaceuticals Inc0.00-13.62m11.10m7.00---------0.1708-0.17080.00-0.0950.00----0.00-181.43-----------------20.00--------89.05------
Apollomics Inc0.00-57.11m11.14m45.00--0.5338-----0.568-0.5680.000.18920.00----0.00-107.81---144.29--------------0.185------28.33------
Data as of Nov 21 2024. Currency figures normalised to Indaptus Therapeutics Inc's reporting currency: US Dollar USD

Institutional shareholders

5.91%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 30 Sep 2024256.27k2.51%
The Investment House LLCas of 30 Sep 202499.98k0.98%
Geode Capital Management LLCas of 30 Sep 202473.13k0.72%
Strategy Asset Managers LLCas of 30 Sep 202445.34k0.45%
Pine Valley Investments LLCas of 30 Jun 202444.09k0.43%
Renaissance Technologies LLCas of 30 Sep 202427.10k0.27%
Vivaldi Capital Management LPas of 30 Sep 202424.00k0.24%
Citadel Securities LLCas of 30 Sep 202415.39k0.15%
SSgA Funds Management, Inc.as of 30 Sep 202413.07k0.13%
Tower Research Capital LLCas of 30 Sep 20244.81k0.05%
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.